柯萨奇B3病毒结构和非结构蛋白基因重组质粒的构建及其在体外真核细胞中的

制备ＣＶＢ３结构蛋白和非结构蛋白重组质粒ＤＮＡ疫苗时,采用ＲＴ－ＰＣＲ从ＣＶＢ感染的ＨｅＬａ细胞中扩增ＶＰ１、ＶＰ２、２Ａ和３Ｄ基因,重组入真核表达质粒ｐｃＤＮＡ３中,构建ｐｃＤＮＡ３／ＶＰ２、ｐｃＤＮＡ３／ＶＰ１、ｐｃＤＮＡ３／２Ａ和ｐｃＤＮＡ３／３Ｄ重组质粒,经酶切和测下实扩增的序列并将各重组质粒体外转染真核细胞ＣＯＳ－７,用ＲＴ－ＰＣＲ检测ｍＲＮＡ的转录,用Ｗｅｓｔｅｒｎ－ｂｌｏｔ检测表达产物。结果４种重组质粒酶切出相应大小的目的片段,经测序证实为ＣＶＢ３相应序列,Ｗｅｓｔｅｒｎ－ｂｌｏｔ证实能够在体外真核细胞中表达。本文成功构建ＣＶＢ３结构与非结构蛋白的重组质粒ＤＮＡ疫苗,为进一步研究其免疫效果奠定了基础。     

丙型肝炎病毒核酸疫苗的免疫效果观察

将丙型肝炎病毒Ｃ＋Ｅ１区基因克隆到不同的真核细胞表达载体ｐＣＤＮＡ３．１（＋）和ｐＳＶＬ中,通过肌肉注射和皮下注射免疫ＢＡＬＢ／Ｃ及Ｆ１小鼠后,产生了抗ＨＣＶ／Ｃ区抗体。其中核酸疫苗ｐｃＤＮＡ３．１－ＨＣＶ／Ｃ＋Ｅ１的免疫高峰的出现早于ｐＳＶＬ－ＨＣＶ／Ｃ＋Ｅ１,Ｆ１小鼠的抗体应答强于ＢＡＬＢ／小鼠。肌肉注射优于皮下注射。     

猪生长激素基因在杆状病毒载体系统中的表达

通过对猪生长激素（ｐＧＨ）基因的ｃＤＮＡ进行测序,得到ｐＧＨｃＤＮＡ的全序列,并与Ｓｅｅｂｕｒｇ等报道的序列进行了比较和讨论。然后利用具人工合成启动子和多角体蛋白ＸＩＶ启动子的转移载体质粒ｐＳＸＩＶＶＩ＾＋Ｘ３／４构建出含ｐＧＨ基因的重组质粒ｐＸ３／４－ｐＧＨ。将ｐＸ３／４－ｐＧＨ与致死缺失型线性化ＡｃＭＮＰＶ－ＯＣＣ＾－ＤＮＡ共转染Ｓｆ９细胞,构建出既能形成多角体又能表达ｐＧＨ基因的苜蓿丫纹夜蛾     

乙肝病毒核衣壳启动子内三链DNA的形成

用电泳迁移分析方法研究了２１ｎｔ脱氧寡核苷酸Ｇ３ＴＧ２ＴＧＴ２Ｇ５ＴＧ２ＴＧＴ（ＣＰ１）与１２９ｂｐ的乙肝病毒（ＨＢＶ）核衣壳启动子（Ｃｐ）片段内一位点结合形成的三链ＤＮＡ的特异性及稳定性．在克隆有ＨＢＶ基因组的质粒ｐＣＰ１０的酶切产物中,ＣＰ１仅与含Ｃｐ的１２９ｂｐ片段结合．在２０ｍｍｏｌ／ＬＭｇ２＋溶液中其解离常数（Ｋｄ）为１．４×１０－７ｍｏｌ／Ｌ．不同离子稳定三链ＤＮＡ的效果依次为ｓｐ４＋（精胺）＞Ｍｇ２＋＞Ｚｎ２＋＞Ｎａ＋＞Ｋ＋,离子之间存在相互竞争作用．比ＣＰ１多一误配碱基的脱氧寡核苷酸Ｇ２ＴＧ２ＴＧＴＧ３ＴＧ２ＴＧ２ＴＧ２Ｔ（ＣＰ２）在２０ｍｍｏｌ／ＬＭｇ２＋溶液中与Ｃｐ结合的Ｋｄ值约为ＣＰ１的１／７,而在６０ｍｍｏｌ／ＬＫ＋或５ｍｍｏｌ／ＬＺｎ２＋溶液中检测不到它与Ｃｐ的结合,这进一步显示了三链ＤＮＡ形成的特异性．细胞的生理离子浓度被认为是：Ｓｐ４＋１ｍｍｏｌ／Ｌ,Ｍｇ２＋１０ｍｍｏｌ／Ｌ,Ｋ＋１４０ｍｍｏｌ／Ｌ,因此,ＣＰ１在细胞内将能特异地与Ｃｐ结合并具有较好的稳定性．     

乙型肝炎病毒preC／C基因在杆状病毒载体系统中的表达

通过ＰＣＲ获得长度为６４０ｂｐ的ＨＢＶ ｐｒｅＣ／Ｃ基因片段,将其克隆入转移载体质粒ｐＳＸＩＶＶＩ＾＋Ｘ３／４,构建出重组质粒ｐＳＸＩＶＶＩ＾＝Ｘ３／４－ｐＣ＝Ｃ。利用共转染的方法,构建出既能形成多角体又能表达ｐｒｅＣ／Ｃ基因的重组毒株ＴｎＮＰＶ－Ｃ／Ｃ－ＯＣＣ＾＋。该重组毒株中ｐｒｅＣ／Ｃ基因受到串联的双启动子－合成启动子和含ＨｉｎｄⅢ接头的ＸＩＶ启动子的双重调控。     

用T-A载体克隆技术构建丙肝病毒C+E1区真核表达质粒pSVL-HCV/C+E1

用ＢａｍＨＩ和ＨｉｎｄＩＩ将丙肝病毒Ｃ＋Ｅ１ＤＮＡ片段从其克隆载体ｐＧＥＭ３ｚｆ－ＨＣＶ／Ｃ＋Ｅ１上切下,经Ｔａｑ酶补齐３’末端后插入到载体ｐＳＶＬ－Ｔ中,构建成丙肝病毒Ｃ＋Ｅ１真核表达载体ｐＳＶＬ－ＨＣＶ／Ｃ＋Ｅ１。本实验中重组效率达６４．７％（１１／１７）,正向插入为５０％（２／４）。     

Epstein—Barr病毒膜抗原基因免疫的研究

将Ｅｐｓｔｅｉｎ－Ｂａｒｒ病毒（ＥＢＶ）膜抗原（ＭＡ）ＢＬＬＦ１基因,插入含有ＣＭＶ启动子的真核表达载体ｐｃＤＮＡ３下游ＢａｍＨＩ位点,构建成真核表达质粒ｐｃＤＮＡ３－ＭＡ。将纯化的ＤＮＡ注射Ｂａｌｂ／ｃ小鼠股四头肌。经免疫的动物产生抗ＥＢ病毒ＭＡ特异性的抗体和中和抗体,依赖抗体细胞介导的细胞毒作用（ＡＤＣＣ）,特异性Ｔ淋巴细胞增生性反应及细胞毒性Ｔ淋巴细胞（ＣＴＬ）杀伤作用。基因免疫与基因－蛋白     

Epstein-Barr病毒膜抗原基因免疫的研究

将Ｅｐｓｔｅｉｎ－Ｂａｒ病毒（ＥＢＶ）膜抗原（ＭＡ）ＢＬＬＦ１基因,插入含有ＣＭＶ启动子的真核表达载体ｐｃＤＮＡ３下游ＢａｍＨＩ位点,构建成真核表达质粒ｐｃＤＮＡ３－ＭＡ。将纯化的ＤＮＡ注射Ｂａｌｂ／ｃ小鼠股四头肌。经免疫的动物产生抗ＥＢ病毒ＭＡ特异性的抗体和中和抗体,依赖抗体细胞介导的细胞毒作用（ＡＤＣＣ）,特异性Ｔ淋巴细胞增生性反应及细胞毒性Ｔ淋巴细胞（ＣＴＬ）杀伤作用。基因免疫与基因－蛋白联合免疫效果相似。不同启动子控制下的ＭＡ基因,诱发小鼠免疫应答无明显差异。     

真菌还原Cr（VI）的研究

从不同来源的样品中分离筛选出几株抗Ｃｒ（ＶＩ）的真菌,他们能在含３００￣５００ｍｇ／ＬＫ２Ｃｒ２Ｏ７的蔗糖合成培养基中生长,其中ＢＳ－１菌株抗Ｋ２Ｃｒ２Ｏ７达９００ｍｇ／Ｌ．ＢＳ－１等４株真菌在含２００ｍｇ／Ｌ Ｋ２Ｃｒ２Ｏ７的培养基中生长４￣６ｄ后,培养液中的Ｃｒ（ＶＩ）已全部消失。这些真菌经鉴定为青霉菌ＢＳ－１和ＢＳ－３,黑曲霉ＢＲ－４和黄曲霉ＢＸ－１。经紫外可见光扫描及化学分析证实,高毒的Ｃ     

鸡传染性支气管炎病毒中国流行株免疫原S1基因的分子克隆、序列分析及其DNA免疫的初步研究

对来源于我国华东地区的鸡传染性支气管炎病毒流行株ＱＤ免疫原Ｓ１基因ｃＤＮＡ进行了克隆、序列分析和ＤＮＡ免疫的初步研究。ＲＴＰＣＲ扩增ＱＤ毒株的Ｓ１基因,将其５′和３′端分别进行分子修饰后插入克隆载体ｐＵＣ１８的ＢａｍＨⅠ／ＨｉｎｄⅢ位点,在大肠杆菌中实现了目的基因的克隆;利用英国ＩＢＶ毒株Ｓ１全基因核酸探针与ＱＤ毒株Ｓ１基因的重组克隆质粒分子杂交后,采用ＨａｅⅢ,ＰｖｕⅡ和ＸｂａⅠ等限制酶对此流行毒株Ｓ１基因ｃＤＮＡ进行了酶切分析;在测定ＱＤ毒株Ｓ１基因５′端高变区核苷酸序列并以此与ＩＢＶＭ４１,Ｈ１２０,６／８２及Ｂｅａｕｄ等参考毒株序列对比分析的基础上,构建了ＱＤ株Ｓ１基因ＤＮＡ免疫表达质粒,肌肉注射免疫小鼠后,鸡胚病毒中和试验的结果表明,ＩＢＶＳ１基因ＤＮＡ免疫表达质粒能诱导小鼠产生病毒特异的中和抗体,具有良好的免疫原性,初步显示基因疫苗在鸡传染性支气管炎防治上应用前景。     

Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7.

Monoclonal antibodies directed against two rotavirus surface proteins (vp3 and vp7) as well as a rotavirus inner capsid protein (vp6) were tested for their ability to protect suckling mice against virulent rotavirus challenge. Monoclonal antibodies to two distinct epitopes of vp7 of simian rotavirus strain RRV neutralized RRV in vitro and passively protected suckling mice against RRV challenge. A monoclonal antibody directed against vp3 of porcine rotavirus strain OSU neutralized three distinct serotypes in vitro (OSU, RRV, and UK) and passively protected suckling mice against OSU, RRV, and UK virus-induced diarrhea. The role of vp3 in eliciting protection against heterotypic rotavirus challenge should be considered when developing a vaccine with cloned rotavirus genes. Alternatively, immunization with a reassortant rotavirus containing vp3 and vp7 from two antigenically distinct rotavirus parents might protect against diarrhea induced by two or more rotavirus serotypes.     

Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone

Schistosomiasis is an endemic disease that affects 200 million people worldwide. DNA-based vaccine is a promising strategy to induce protective immunity against schistosomiasis, since both humoral and cellular immune responses are involved in parasite elimination. In this study, we evaluated the ability of Sm14 cDNA alone or in association with a plasmid expressing murine interleukin (IL)-12 to induce protection against challenge infection. Mice were immunized with four doses of the DNA vaccine and the levels of protection were determined by worm burden recovery after challenge infection. Specific antibody production to rSm14 was determined by ELISA, and cytokine production was measured in splenocyte culture supernatants stimulated with rSm14 and in bronchoalveolar lavage of vaccinated mice after challenge infection. DNA immunization with pCI/Sm14 alone induced 40.5% of worm reduction. However, the use of pCI/IL-12 as adjuvant to pCI/Sm14 immunization failed to enhance protection against challenge infection. Protection induced by pCI/Sm14 immunization correlates with specific IgG antibody production against Sm14, Th1 type of immune response with high levels of interferon (IFN)-gamma and low levels of IL-4 in splenocyte culture supernatants and in bronchoalveolar lavage after challenge infection. IL-12 co-administration with pCI/Sm14 induced a significant production of nitric oxide in splenocyte culture supernatants and also lymphocyte suppression, with reduced percentage of T cells producing IFN-gamma and tumor necrosis factor-alpha.     

A组轮状病毒多个结构蛋白抗原表位的串联表达及其免疫原性的检测

从北京腹泻婴儿粪便提取的轮状病毒(rotavirus,RV)(T114株)的RNA中,克隆到轮状病毒结构蛋白基因vp4,vp6和vp7的全长cDNA,对它们编码的蛋白质序列和可能的抗原表位肽进行了预测,选择了RV主要抗原蛋白VP7、VP6和VP4的4个抗原表位肽,通过人工合成DNA的方式将这些抗原表位肽基因串联融合成一个阅读框RME(rotavirus multipleepitopes,RME)并构建原核表达载体.大肠杆菌表达的RME在ELISA反应中可被RV多克隆抗体识别,纯化的RME蛋白注射免疫小鼠可诱导特异性免疫应答,产生高滴度的同源氨基酸序列特异抗体和人RV抗体,其中针对RME的IgG抗体滴度达到l∶40 000,针对单个抗原表位EV7、EV6和EV4的IgG抗体滴度达l∶10 000～l∶20 000,针对RV Wa株的IgG抗体滴度较低为l∶2 500,但能特异地中和该病毒对MAC145细胞的侵染.上述结果为新型RV基因工程疫苗的研发提供了论据和基础.     

Rotavirus virus-like particles administered mucosally induce protective immunity.

We have evaluated the immunogenicity and protective efficacy of rotavirus subunit vaccines administered by mucosal routes. Virus-like particles (VLPs) produced by self-assembly of individual rotavirus structural proteins coexpressed by baculovirus recombinants in insect cells were the subunit vaccine tested. We first compared the immunogenicities and protective efficacies of VLPs containing VP2 and VP6 (2/6-VLPs) and G3 2/6/7-VLPs mixed with cholera toxin and administered by oral and intranasal routes in the adult mouse model of rotavirus infection. VLPs administered orally induced serum antibody and intestinal immunoglobulin A (IgA) and IgG. The highest oral dose (100 microg) of VLPs induced protection from rotavirus challenge (> or = 50% reduction in virus shedding) in 50% of the mice. VLPs administered intranasally induced higher serum and intestinal antibody responses than VLPs administered orally. All mice receiving VLPs intranasally were protected from challenge; no virus was shed after challenge. Since there was no difference in immunogenicity or protective efficacy between 2/6- and 2/6/7-VLPs, protection was achieved without inclusion of the neutralization antigens VP7 and VP4. We also tested the immunogenicities and protective efficacies of 2/6-VLPs administered intranasally without the addition of cholera toxin. 2/6-VLPs administered intranasally without cholera toxin induced lower serum and intestinal antibody titers than 2/6-VLPs administered with cholera toxin. The highest dose (100 microg) of 2/6-VLPs administered intranasally without cholera toxin resulted in a mean reduction in shedding of 38%. When cholera toxin was added, higher levels of protection were achieved with 10-fold less immunogen. VLPs administered mucosally offer a promising, safe, nonreplicating vaccine for rotavirus.     

Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype.

Genetic studies of reassortant rotaviruses have demonstrated that gene segments 4 and 9 each segregate with the serotype-specific neutralization phenotype in vitro. Reassortant rotaviruses derived by coinfection of MA-104 cells with the simian strain SA11 and the antigenically distinct bovine strain NCDV were used to determine which viral genes coded for proteins which induced a protective immune response in vivo. In addition, reassortant rotaviruses containing only the gene segment 4 or 9 protein products (vp3 and vp7, respectively) from SA11 or NCDV were used to determine the serotypic specificities of both vp3 and vp7 in several mammalian rotavirus strains. vp3 and vp7 from the murine strain Eb were shown to be indistinguishable from the corresponding proteins from strain SA11. Adult mice orally inoculated with strain Eb developed neutralizing antibodies to both vp3 and vp7. The two naturally occurring bovine rotavirus strains NCDV and UK were shown to contain antigenically similar vp7 but distinct vp3 proteins. Mouse dams orally immunized with a reassortant virus containing only gene 9 from NCDV passively protected their progeny against UK challenge, whereas mouse dams orally immunized with a reassortant virus containing only gene 4 from NCDV did not. Finally, we constructed reassortant viruses that immunized against rotaviruses of two distinct serotypes. SA11 X NCDV reassortants that contained vp3 and vp7 from different parents induced a protective immune response against both parental serotypes. vp3 and vp7 were independently capable of inducing a protective immune response after oral immunization. An understanding of the serotypic specificities of both vp3 and vp7 of human rotavirus isolates will be necessary for the development of successful strategies to protect infants against severe rotavirus infections.     

Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles

The recognition that rotaviruses are the major cause of life-threatening diarrheal disease and significant morbidity in young children has focused efforts on disease prevention and control of these viruses. Although the correlates of protection in children remain unclear, some studies indicate that serotype-specific antibody is important. Based on this premise, current live attenuated reassortant rotavirus vaccines include the four predominant serotypes of virus. We are evaluating subunit rotavirus vaccines, 2/6/7-VLPs and 2/4/6/7-VLPs, that contain only a single VP7 of serotype G1 or G3. In mice immunized parenterally twice, G3 virus-like particles (VLPs) induced a homotypic, whereas G1 VLPs induced a homotypic and heterotypic (G3) serum neutralizing immune response. Administration of three doses of G1 or G3 VLPs induced serum antibodies that neutralized five of seven different serotype test viruses. The inclusion of VP4 in the VLPs was not essential for the induction of heterotypic neutralizing antibody in mice. To confirm these results in another species, rabbits were immunized parenterally with two doses of 2/4/6/7-VLPs containing a G3 or G1 VP7, sequentially with G3 VLPs followed by G1 (G3/G1) VLPs, or with live or psoralen-inactivated SA11. High-titer homotypic serum neutralizing antibody was induced in all rabbits, and low-level heterotypic neutralizing antibody was induced in a subset of rabbits. The rabbits immunized with the G1 or G3/G1 VLPs in QS-21 were challenged orally with live G3 ALA rotavirus. Protection levels were similar in rabbits immunized with homotypic G3 2/4/6/7-VLPs, heterotypic G1 2/4/6/7-VLPs, or G3/G1 2/4/6/7-VLPs. Therefore, G1 2/4/6/7-VLPs can induce protective immunity against a live heterotypic rotavirus challenge in an adjuvant with potential use in humans. Following challenge, broad serum heterotypic neutralizing antibody responses were detected in rabbits parenterally immunized with G1, G3/G1, or G3 VLPs but not with SA11. Immunization with VLPs may provide sufficient priming of the immune system to induce protective anamnestic heterotypic neutralizing antibody responses upon subsequent rotavirus infection. Therefore, a limited number of serotypes of VLPs may be sufficient to provide a broadly protective subunit vaccine.     

Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants

The human pathogen, group A rotavirus, is the most prevalent cause of acute infantile and pediatric gastroenteritis worldwide, especially in developing countries. There is an urgent demand for safer, more effective and cheaper vaccines against rotavirus infection. Plant-derived antigens may provide an exclusive way to produce economical subunit vaccines. Virus-like particles, constituting viral capsid proteins without viral nucleic acids, are considered a far safer candidate compared with live attenuated viral vaccines. In this study, the rotavirus capsid proteins VP2, VP6 and VP7 were co-expressed in transgenic tobacco plants, and their expression levels, formation of rotavirus-like particles (RV VLPs) and immunogenicity were extensively studied. Quantitative real-time RT-PCR and Western blot analysis revealed that the expression level of vp6 was the highest while vp7 was expressed at the lowest levels. The RV VLPs were purified from transgenic tobacco plants and analyzed by electron microscopy and Western blot. Results indicated that the plant-derived VP2, VP6 and VP7 proteins self-assembled into 2/6 or 2/6/7 RV VLPs with a diameter of 60–80 nm. When orally delivered into mice with cholera toxin as an adjuvant, the total soluble protein extracted from transgenic tobacco plants induced rotavirus-specific antibodies comparable with those of attenuated rotavirus vaccines, while VP 2/6/7 induced higher serum IgG and fecal IgA titers compared with VP 2/6.     

Lack of cosegregation of the subgroup II antigens on genes 2 and 6 in porcine rotaviruses.

The rotavirus subgroup I and II specificities associated with gene 2 and 6 products (vp2 and vp6, respectively) were shown not to cosegregate in a number of porcine rotavirus strains. The porcine OSU rotavirus strain and OSU-vp7-like strains were all found to possess a subgroup II-specific region on vp2 and a subgroup I-specific region on vp6. Of interest is the observation that the subgroup II-specific epitope on vp2 appears to be present only in human and porcine rotavirus strains, suggesting a possible human-pig ancestral lineage for gene 2.     

Heterotypic passive protection induced by synthetic peptides corresponding to VP7 and VP4 of bovine rotavirus.

We have evaluated the potential of two peptides derived from highly conserved regions of rotavirus outer capsid proteins (VP7 and VP4) to act as a rotavirus vaccine. The capacity of peptides coupled to rotavirus VP6 spherical particles to provide passive protection in a murine model was compared with the protection induced by peptide-keyhole limpet hemocyanin (KLH) conjugates. Female mice were immunized a total of three times before and during pregnancy. Suckling mouse pups were challenged at 7 days of age with either homologous or heterologous rotavirus serotypes. The efficacy of vaccination was determined by analyzing the clinical symptoms and measuring xylose adsorption in the intestine. In this model the VP4 peptide-VP6 conjugate provided protection equal to that obtained using bovine rotavirus (BRV) as the immunogen. The VP7 peptide-VP6 conjugate provided slightly less protection than the VP4 peptide-VP6 conjugate. A mixture of the VP4 peptide-VP6 and VP7 peptide-VP6 conjugates provided better heterologous protection than immunization with BRV. In contrast, KLH-conjugated peptides provided only partial protection. The significance of a synthetic-peptide-based rotavirus vaccine in the prevention of rotavirus infections is discussed.     

猪轮状病毒vp4基因的克隆及其在昆虫细胞中的表达

本研究扩增猪轮状病毒中国分离株JL94株VP4蛋白主要抗原编码区基因(1-756bp),将测序结果与国外分离株进行比较;将该基因片段同载体pMel BacA连接后,与杆状病毒DNA共转染入昆虫细胞Sf9,经蚀斑筛选纯化重组病毒并再感染Sf9细胞获得vp4基因的表达,对表达的VP4蛋白进行Western blot分析和血清中和抗体试验。结果表明：JL94株VP4主要抗原编码区基因与国外分离株CRW-8株、Gottfried株该基因片段氨基酸同源性分别为96．43％和67％,说明JL94株与CRW-8株属同一VP4血清型,而与Gottfried株属不同血清型。JL94株vP4主要抗原编码区氨基酸最大变异处位于aa81-aa207。vp4基因在昆虫细胞中表达量占细胞总蛋白的20％,Western Blot证实表达蛋白有良好的生物学活性。所表达的蛋白免疫小鼠产生中和抗体,阻断JL94在MA104细胞上引起的细胞病变。